{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.948"},{"groupId":"OG001","value":"0.951"}]}],"title":"Proportion of participants with durable graft"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.052"},{"groupId":"OG001","value":"0.049"}]}],"title":"Proportion of participants without durable graft"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \\>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \\>=10g/dL for at least 1 month, (3) and absolute neutrophil count \\>1000/µL for at least 1 week.","groups":[{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"G-CSF Plus Plerixafor"},{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"G-CSF Plus Placebo"}],"paramType":"NUMBER","populationDescription":"Participants who received a stem cell transplant and were evaluable at 100 days post-transplant","reportingStatus":"POSTED","timeFrame":"approximately Day 138","title":"Graft Durability at 100 Days Post Transplantation","type":"SECONDARY","unitOfMeasure":"proportion of participants"}